Results 261 to 270 of about 495,708 (385)

Cancer and Placebos [PDF]

CA: A Cancer Journal for Clinicians, 1981
openaire   +2 more sources

Population pharmacokinetics of TBAJ‐587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection

British Journal of Clinical Pharmacology, EarlyView.
Background and Aim The rise of drug‐resistant tuberculosis (TB) poses a need for new drugs and combinations. TBAJ‐587, a new diarylquinoline (DARQ), has shown promising efficacy in preclinical studies. This work aimed to describe the pharmacokinetics (PK) of TBAJ‐587 and its metabolites M2 and M3 after single ascending dosing in healthy volunteers and ...
Albin A. M. Leding, Paul Bruinenberg, Almari Conradie, Jerry Nedelman, Antonio Lombardi, Dean Hickman, Ulrika S. H. Simonsson   +6 more
wiley   +1 more source

Open-Label-Placebos can reduce pain, but not indigestion during gluten challenge in chronic pain patients. [PDF]

Front Psychol
Paschke-Dahl L, Klinger R.
europepmc   +1 more source

Can probiotics prevent acute radiation-induced diarrhoea among cervical cancer patients?: the result from a randomized double-blinded placebo-controlled study

, 2018
Ye Htut Linn, K Khine Thu, Nang Hla Hla Win   +2 more
openalex   +2 more sources

Paternalism, Placebos, and Informed Consent in Psychotherapy

, 2016
C. Blease, M. Trachsel, M. Holtforth
semanticscholar   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

Effects of open-label placebos and self-monitoring in skin-picking disorder: a randomized crossover trial. [PDF]

Front Psychiatry
Schienle A, Wabnegger A, Tanzmeister S.
europepmc   +1 more source

Some Ethical Reflections on AIDS [PDF]

, 1988
LaChat, Michael
core   +1 more source

CTIM-14. EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM) [PDF]

J. Bradley Elder, Simon Hanft, Ian Lee, Christopher Farrell, John A. Boockvar, Brad E. Zacharia, Lyndon Kim, Michael Schulder, Carlos Eduardo Silva Correia, Rohan Ramakrishna, Eric T. Wong, Julian K. Wu, Vijay Agarwal, Rose Du, Ankush Bhatia, Linton T. Evans, Cameron Brennan, Brian Gill, Soma Sengupta, Alfredo Quiñones-Hinojosa, Pierre Giglio, Kyle C. Wu, Synphen H. Wu, Cristina Falo, Tobias Walbert, Adam Robin, Iyad Alnahhas, Morana Vojnic, A. Gabriella Wernicke, Dawit Aregawi, Robert Maurer, Saadi Ghatan, Samuel Singer, Suriya Jeyapalan, Rajiv Magge, Athar N. Malik, Nitesh V. Patel, Amy B. W. Chan, Fábio M. Iwamoto, Adı́lia Hormigo, Dominique Higgins, Mahua Dey, Nelson S. Moss, Wendy Sherman, Laura L. Neese, Gregory Pennock, Charles Scott, Raul Perez-Olle, David W. Andrews   +48 more
openalex   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source